Lowenstein represented Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (Spring Bank), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, in the completion of its business combination with F-star Therapeutics Limited (F-star), in which Spring Bank acquired all of the outstanding share capital of F-star in exchange for newly issued shares of Spring Bank in a share exchange conducted under English law.
The corporate name of Spring Bank has changed from "Spring Bank Pharmaceuticals, Inc." to "F-star Therapeutics, Inc.” F-star’s shareholders now own approximately 53.7 percent of the combined company, and Spring Bank stockholders now own approximately 46.3 percent of the combined company.
The deal team consisted of John D. “Jack” Hogoboom, Daniel C. Porco, Madeline Roe, Andrew E. Graw, Brian A. Silikovitz, Robert J. Paradiso, James C. Shehan, Bryan Sterba, Bettina C. Elstroth and Keith Janowitz.
About Lowenstein Sandler LLP
Lowenstein Sandler is a national law firm with more than 350 lawyers based in New York, Palo Alto, New Jersey, Utah, and Washington, D.C. The firm represents leaders in virtually every sector of the global economy, with particular emphasis on investment funds, life sciences, and technology. Recognized for its entrepreneurial spirit and high standard of client service, the firm is committed to the interests of its clients, colleagues, and communities.
Stephen J. Kimmerling
Director, Marketing Communications
Lowenstein Sandler LLP
T: +1 973.597.6176